1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Pfizer Inc.

Pfizer Inc.

PFE.BA
Pfizer Inc.AR flagBuenos Aires Stock Exchange
9,350.00
ARS
-425.00
- -
212.37TMarket Cap
Pfizer Inc.
PFE.BA
(Buenos Aires Stock Exchange)

Recent

price

9,350.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
16.22
15.62
14.69
15.14
15.63
15.82
17.35
17.6
13.9
14.69
15
29.03
36.08
21.11
22.47
22.02
22.26
Revenue per Share
2.05
2.56
3.92
6.46
2.88
2.25
2.37
7.14
3.8
5.76
3.3
7.85
11.19
0.75
2.84
2.73
2.63
Basic EPS, GAAP
2.47
4.7
4.12
4.76
4.89
4.27
4.66
4.89
4.66
3.64
4.19
10.67
9.28
1.7
3.47
3.19
3.33
Free Cash Flow per Basic Share
1.52
1.59
1.76
1.93
2.08
2.25
2.4
2.57
2.72
2.89
3.04
3.12
3.2
3.28
3.36
3.44
3.44
Dividend per Share
10.74
11.94
14.7
20.6
22.89
23.46
23.73
28.73
30.66
35.24
32.71
37.09
44.98
42.12
41.39
40.5
41.4
Book Value per Share
-3.31
-3.37
-1.93
-1.56
-1.78
-7.65
-15.53
-11.07
-8.48
-6.72
-5.19
1.11
0.42
-15.38
-12.51
-13.45
-11.8
Tangible Book Value per Share
4,018
3,908
3,721
3,406
3,173
3,088
3,044
2,985
2,936
2,784
2,778
2,800
2,804
2,822
2,832
2,842
2,844
Basic Weighted Avg Shares
65,165
61,035
54,657
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,314
Sales/Revenue/Turnover
25.41
27.54
31.24
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
27.24
Operating Margin (%)
8,399
9,026
7,655
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,587
Depreciation Expense
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
7,490
Net Income, GAAP
12.17
31.54
19.76
27.4
25.49
22.2
13.45
- -
- -
5.15
5.26
7.62
9.58
- -
- -
- -
4.86
Effective Tax Rate (%)
12.67
16.4
26.66
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
11.83
Profit Margin (%)
31,859
31,908
35,645
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
8,474
Working Capital
38,410
34,926
31,036
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
59,840
LT Debt
88,265
82,621
81,678
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
90,404
Total Equity
9.82
9
11.32
10.19
9.07
9.57
11.67
- -
- -
6.29
8.3
20.13
27.89
- -
- -
- -
10.54
Return on Invested Capital (%)
11.03
12.8
17.64
23
9.34
7.15
7.33
- -
- -
12.45
7.53
17.1
21.47
- -
- -
- -
5.5
Return on Capital (%)
19.65
22.28
28.75
35.24
12.79
9.59
9.97
26.97
12.69
17.03
9.69
22.57
27.28
1.73
6.8
6.69
6.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,303
3,154
3,890
LT Borrowings
56,545
60,807
59,840
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,686
5,686
5,699
Market Capitalization
20,094
18,566
21,135

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
46,924
42,898
42,822
Cash, Cash Equivalents & STI
14,984
13,596
13,075
Accounts Receivable, Net
14,260
11,874
12,585
Inventories
11,468
10,654
10,667
Total Current Liabilities
36,596
36,984
34,348
Payables & Accruals
8,823
10,788
7,636
ST Debt
4,303
3,154
3,890
Deferred Revenue
924
784
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.1
0.01
1.58
0.14
2.84
2025
1.05
1.02
- -
-0.58
2.73
2026
0.94
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.84
0.84
0.84
0.84
3.36
2025
0.86
0.86
- -
0.86
3.44
2026
0.86
- -
- -
- -
- -
Similar Companies
Otsuka Holdings Co., Ltd. (4578.T)
Grifols, S.A. (GIKLY)
Daiichi Sankyo Company, Limited (DSNKY)
Kyowa Kirin Co., Ltd. (KYKOF)
Zhejiang Zhenyuan Share Co., Ltd. (000705.SZ)
Chugai Pharmaceutical Co., Ltd. (4519.T)
Business
Pfizer Inc. (NYSE: PFE; BCBA: PFE) develops, manufactures and markets biopharmaceutical products worldwide, including innovative medicines and vaccines targeting immunology, oncology, cardiology, endocrinology, neurology, rare diseases, inflammation, internal medicine and infectious diseases; principal products comprise Eliquis (apixaban, anticoagulant), Prevnar family (pneumococcal conjugate vaccines), Paxlovid (COVID-19 oral antiviral), Vyndaqel (tafamidis, for transthyretin amyloid cardiomyopathy), Comirnaty (COVID-19 vaccine with BioNTech), Ibrance (palbociclib, breast cancer therapy), alongside vaccines for respiratory syncytial virus (Abrysvo), meningococcal disease (Penbraya), influenza and others, cardiovascular therapies, oncology treatments including antibody-drug conjugates from Seagen, internal medicine offerings for obesity, type 2 diabetes and metabolic disorders, and inflammation/immunology drugs for rheumatoid arthritis, lupus and atopic dermatitis. The company, founded in 1849 by Charles Pfizer and Charles F. Erhart and headquartered at The Spiral in Hudson Yards, Manhattan, New York City, operates globally with major revenues from the United States (61% in 2024), China and other international markets, ranking fifth among largest biomedical companies by revenue and maintaining research facilities in Groton, Connecticut, the United Kingdom and India. Pfizer focuses on precision medicine, immunotherapy, gene therapy, mRNA technologies and AI-driven drug discovery, with a pipeline exceeding 100 candidates across Phase 1 to Registration stages as of November 2025, emphasizing oncology breakthroughs, obesity treatments like danuglipron (oral GLP-1 agonist), and next-generation vaccines. Recent developments include the November 2025 completion of its $7.0 billion acquisition of Metsera Inc., adding clinical-stage obesity and cardiometabolic assets such as MET-097i (injectable GLP-1 receptor agonist entering Phase 3), MET-233i (amylin analog), and oral GLP-1 candidates to bolster the internal medicine portfolio; a July 2024 Innovation Supply Chain partnership with Flagship Pioneering committing $50 million each to co-develop up to 10 drug candidates in obesity and cardiovascular areas with potential milestones up to $700 million per program; expanded AI collaborations with Saama for clinical trials and Ignition AI Accelerator for drug discovery and manufacturing optimization; and divestiture of its remaining stake in Haleon (consumer health joint venture with GlaxoSmithKline) in March 2025 for $3.24 billion to sharpen focus on innovative biopharma, alongside the 2023 $43 billion acquisition of Seagen enhancing oncology capabilities.